AYTU
AYTU BIOPHARMA, INC
+0.03 (+1.78%)2.01USD3.7K成交股數21.5M市值–本益比(近四季)0.4股價營收比-32.7%營收年增(近四季)–下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 6 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 12.4M-33% | 15.2M-7% | 13.9M-16% | 15.1M+8% | 18.5M-2% | 16.2M-9% | 16.6M-46% | 14.0M-38% | 18.7M | 17.8M | 30.7M | 22.7M |
| 營業成本 | 4.8M | 5.5M | 4.7M | 4.9M | 5.6M | 5.4M | 4.6M | 3.7M | 4.1M | 4.8M | 12.2M | 10.0M |
| 毛利 | 7.6M-41% | 9.6M-11% | 9.2M-23% | 10.3M-1% | 12.8M-12% | 10.8M-17% | 12.0M-35% | 10.4M-19% | 14.6M | 13.0M | 18.6M | 12.7M |
| 毛利率 | 61.2% | 63.5% | 66.1% | 67.8% | 69.4% | 66.5% | 72.3% | 73.9% | 77.9% | 73.2% | 60.4% | 56.1% |
| 研發費用 | 0.00 | 0.00 | 0.00 | 216K | 162K | 522K | 426K | 611K | 521K | 595K | 465K | 856K |
| 銷售管理費用 | 5.0M | 5.1M | 4.9M | 3.7M | 4.1M | 4.4M | 5.1M | 4.8M | 4.8M | 6.3M | 6.1M | 7.2M |
| 營業利益 | −4.1M-268% | −2.0M+16% | −1.5M+62% | −7.6M+377% | 2.4M-23% | −1.7M+96% | −930K-650% | −1.6M-81% | 3.1M | −867K | 169K | −8.6M |
| 營業利益率 | -32.7% | -13.0% | -10.8% | -50.4% | 13.1% | -10.4% | -5.6% | -11.4% | 16.8% | -4.9% | 0.5% | -37.6% |
| 稅後淨利 | −5.6M-241% | −10.6M-1443% | 2.0M+33% | −19.8M+586% | 4.0M-1915% | 788K-110% | 1.5M-160% | −2.9M-60% | −220K | −8.1M | −2.5M | −7.2M |
| 淨利率 | -45.3% | -69.8% | 14.1% | -130.9% | 21.6% | 4.9% | 8.9% | -20.6% | -1.2% | -45.6% | -8.0% | -31.7% |
| 稀釋 EPS | -0.53-352% | -1.05+304% | -0.08-47% | – | 0.21-625% | -0.26-82% | -0.15-80% | -0.52-73% | -0.04 | -1.48 | -0.75 | -1.93 |
| 稀釋股數 | 10.5M | 10.0M | 19.5M | – | 8.2M | 8.5M | 9.1M | 5.5M | 5.5M | 5.5M | 3.3M | 3.7M |
資產負債表 期末餘額
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 26.7M | 30.0M | 32.6M | 31.0M | 18.2M | 20.4M | 20.1M | 19.8M | 19.5M | 20.0M | 23.0M | 19.2M |
| 應收帳款 | 24.5M | 30.9M | 33.2M | 31.2M | 35.8M | 25.4M | 23.2M | 29.9M | 29.4M | 29.9M | 28.9M | 34.0M |
| 存貨 | 7.5M | 8.7M | 10.1M | 11.4M | 11.1M | 11.1M | 11.7M | 13.2M | 13.0M | 13.0M | 12.0M | 13.6M |
| 總資產 | 112M | 122M | 125M | 124M | 124M | 116M | 116M | 129M | 131M | 133M | 136M | 147M |
| 有息負債 | 9.5M | 10.0M | 10.4M | 10.9M | 9.5M | 10.0M | 10.4M | 0.00 | 15.0M | 15.0M | 14.7M | 15.0M |
| 總負債 | – | – | – | – | – | – | – | – | – | 101M | 97.1M | 106M |
| 股東權益 | 35.1M | 14.2M | 23.2M | 19.0M | 34.9M | 30.8M | 29.8M | 30.8M | 32.9M | 32.2M | 39.4M | 40.9M |
| 負債比 | – | – | – | – | – | – | – | – | – | 75.8% | 71.2% | 72.2% |
| 淨現金(現金 − 有息負債) | 17.2M | 20.0M | 22.2M | 20.1M | 8.6M | 10.4M | 9.7M | 19.8M | 4.6M | 5.0M | 8.3M | 4.2M |
現金流量表 單季
| 科目 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | – | −618K-48% | – | – | – | −1.2M | – | – | −211K | – | – |
| 資本支出 | – | – | 0.00 | – | – | – | 136K | – | – | – | – | – |
| 自由現金流 | – | – | −618K-53% | – | – | – | −1.3M | – | – | – | – | – |
| 折舊攤銷 | – | – | 803K | – | – | – | 1.3M | 1.8M | 1.9M | 2.2M | 2.8M | 1.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | -4.4% | – | – | – | -8.0% | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 66.4M
| Rx | 66.4M | 100.0% | +1.8% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 66.4M | +1.8% | −13.6M | -20.4% | – | −2.2M |
| FY2024 | 65.2M | -39.3% | −15.8M | -24.3% | – | −1.7M |
| FY2023 | 107M | +11.1% | −17.1M | -15.9% | -5.11 | – |
| FY2022 | 96.7M | +47.3% | −109M | -112.5% | -74.01 | −28.8M |
| FY2021 | 65.6M | +137.5% | −58.3M | -88.8% | -3.48 | −28.3M |
| FY2020 | 27.6M | +277.5% | −13.6M | -49.3% | -3.01 | −28.4M |
| FY2019 | 7.3M | – | −27.1M | -370.6% | -3.48 | −13.9M |